Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum93682ArticlesСтатьиResearch ArticleA-streptokokkovyy tonzillit: voprosy antibakterial'noy terapiiА-стрептококковый тонзиллит: вопросы антибактериальной терапииBelovB. SБеловБ. СФГБУ Научно-исследовательский институт ревматологии РАМН151120121411VOL 14, NO11 (2012)ТОМ 14, №11 (2012)253228122021Copyright ©; 2012, Consilium MedicumCopyright ©; 2012, ООО "Консилиум Медикум"2012Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/93682

Острый тонзиллит (ангина) характеризуется острым воспалением одного или нескольких лимфоидных образований глоточного кольца(чаще – небных миндалин) и принадлежит к числу широко распространенных инфекционных заболеваний верхних дыхательных путей.В настоящее время канадскими авторами разработан и апробирован на большой группе пациентов клинический алгоритм, позволяющий при первом осмотре больного предположить наличие БГСА - инфекции глотки и, соответственно, решить вопрос о назначении эмпирической антимикробной терапии при невозможности выполнения микробиологического исследования. Учитывая возможность спонтанного купирования клинической симптоматики БГСА - тонзиллита и выздоровления без каких-либо осложнений, некоторые врачи при курации таких больных совершенно необоснованно отдают предпочтение местному лечению (полоскание, ингаляции и т.д.) в ущерб системной антибиотикотерапии. Подобный подход представляется совершенно неправильным и даже вредным для больного из-за угрозы развития весьма серьезных последствий. На сегодняшний день истинные причины упомянутого «возрождения» высоковирулентной БГСА - инфекции остаются полностью не раскрытыми. В связи с этим точный диагноз и обязательная рациональная антибиотикотерапия БГСА - тонзиллита (в том числе его малосимптомных форм) стали играть еще более важную роль как в контроле за распространением этих инфекций, так и в профилактике осложнений.

Bisno A.L. Acute pharyngitis: etiology and diagnosis. Pediatrics 1996; 97 (Suppl.): 944–9.Wannamaker L.W. Perplexity and precision in the diagnosis of streptococcal pharyngitis. Am J Dis Child 1972; 124: 352–8.Pfoh E, Wessels M.R., Goldmann D, Lee G.M. Burden and economic cost of group A streptococcal pharyngitis. Pediatrics 2008; 121 (2): 229–34.Беляков В.Д. Сюрпризы стрептококковой инфекции. Вестн. РАМН, 1996; 11: 24–8.Kaplan E.L. Global assessment of rheumatic fever and rheumatic heart disease at the close of the century. Influences and dynamics of populations and pathogens: a failure to realize prevention? Circulation 1993; 88 (4–1): 1964–72.Pastore S, De Cunto A, Benettoni A et al. The resurgence of rheumatic fever in a developed country area: the role of echocardiography. Rheumatology 2011; 50 (2): 396–400.Vinker S, Zohar E, Hoffman R, Elhayany A. Incidence and clinical manifestations of rheumatic fever: a 6 year community - based survey. Isr Med Assoc J 2010; 12 (2): 78–81.Насонова В.А., Белов Б.С., Страчунский Л.С. и др. Антибактериальная терапия стрептококкового тонзиллита (ангины) и фарингита. Рос. ревматология. 1999; 4: 20–7.Богомильский М.Р. Детская оториноларингология. М.: Гэотар-Медиа, 2006.Mc Isaac W.J., Goel V, To T, Low D.E. The validity of a sore throat score in family practice. CMAJ 2000; 163 (7): 811–5.Jersid T. Penicillin therapy in scarlet fever and complicating otitis. Lancet 1948; 1: 671–3.Rammelkamp C.H., Wannamaker L.W., Denny F.W. The epidemiology and prevention of rheumatic fever. Bull. New York Acad Med 1952; 2 (5): 321–4.Ginsburg C.M., Mc Cracken G.H. Jr., Steinberg J.B. et al. Treatment of Group A streptococcal pharyngitis in children. Results of a prospective, randomized study of four antimicrobial agents. Clin Pediatr (Phila) 1982; 21 (2): 83–8.Kafetzis D.A., Liapi G, Tsolia M et al. Failure to eradicate Group A beta - haemolytic streptococci (GABHS) from the upper respiratory tract after antibiotic treatment. Int J Antimicrob Agents 2004; 23 (1): 67–71.Mc Carty J.M. Comparative efficacy and safety of cefprozil versus penicillin, cefaclor and erythromycin in the treatment of streptococcal pharyngitis and tonsillitis. Eur J Clin Microbiol Infect Dis 1994; 13 (10): 846–50.Holm S.E. Reasons for failures in penicillin treatment of streptococcal tonsillitis and possible alternatives. Pediatr Infect Dis J 1994; 13 (1 Suppl. 1): 66–9.Still J.G. Treatment of streptococcal pharyngitis in children with five days of azithromycin suspension. Proc. 34th Ann Meeting ICAAC. Orlando (Florida) 1994; Abstr. M67.Roos K, Larsson P. Loracarbef versus phenoxymethylpenicillin in the treatment of recurrent streptococcal pharyngotonsillitis. Scand J Infect Dis 1997; 29 (2): 141–5.Bergman A, Werner R. Failure of children to receive penicillin by mouth. N Engl J Med 1963; 268: 1334–8.Brook I. The role of beta - lactamase producing bacteria and bacterial interference in streptococcal tonsillitis. Int J Antimicrob Agents 2001; 17 (6): 439–42.Brook I, Gober A.E. Persistence of group A beta - hemolytic streptococci in toothbrushes and removable orthodontic appliances following treatment of pharyngotonsillitis. Arch Otolaryngol Head Neck Surg 1998; 124 (9): 993–5.Roos K, Holm S.E., Grahn-Hakansson E, Lagergren L. Recolonization with selected alpha - streptococci for prophylaxis of recurrent streptococcal pharyngotonsillitis – a randomized placebo - controlled multicentre study. Scand J Infect Dis 1996; 28 (5): 459–62.Shaikh N, Leonard E, Martin J.M. Prevalence of streptococcal pharyngitis and streptococcal carriage in children: a meta - analysis. Pediatrics 2010; 126 (3): e557–64.Sela S, Barzilai A. Why do we fail with penicillin in the treatment of group A streptococcus infections? Ann Med 1999; 31: 303–7.Kaplan E.L., Chhatwal G.S., Rohde M. Reduced ability of penicillin to eradicate ingested group A streptococci from epithelial cells: clinical and path genetic implications. Clin Infect Dis 2006; 43 (11): 1398–406.Gerber M.A., Baltimore R.S., Eaton C.B. et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2009; 119 (11): 1541–51.Shulman S.T., Bisno A.L., Clegg H.W. et al. Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America. Clin Infect Dis 2012; 9.Lennon D.R., Farrell E, Martin D.R., Stewart J.M. Once - daily amoxicillin versus twice - daily penicillin V in group A beta - haemolytic streptococcal pharyngitis. Arch Dis Child 2008; 93 (6): 474–8.Clegg H.W., Ryan A.G., Dallas S.D. et al. Treatment of streptococcal pharyngitis with once - daily compared with twice - daily amoxicillin: a noninferiority trial. Pediatr Infect Dis J 2006; 25 (9): 761–7.Shvartzman P, Tabenkin H, Rosentzwaig A, Dolginov F. Treatment of streptococcal pharyngitis with amoxycillin once a day. BMJ 1993; 306 (6886): 1170–2.Feder H.M., Gerber M.A., Randolph M.F. et al. Once - daily therapy for streptococcal pharyngitis with amoxicillin. Pediatrics 1999; 103 (1): 47–51.Regoli M, Chiappini E, Bonsignori F et al. Update on the management of acute pharyngitis in children. Ital J Pediatr 2011; 37: 10.Chiappini E, Regoli M, Bonsignori F et al. Analysis of different recommendations from international guidelines for the management of acute pharyngitis in adults and children. Clin Ther 2011; 33 (1): 48–58.Zavadska D, Bērziņa D, Drukaļska L et al. Macrolide resistance in group A beta haemolytic Streptococcus isolated from outpatient children in Latvia. APMIS 2010; 118 (5): 366–70.Savoia D, Avanzini C, Bosio K et al Macrolide resistance in group A streptococci. J Antimicrob Chemother 2000; 45: 41–7.Silva-Costa C, Ramirez M, Melo-Cristino J. Rapid inversion of the prevalences of macrolide resistance phenotypes paralleled by a diversification of T and emm types among Streptococcus pyogenes in Portugal. Antimicrob Agents Chemother 2005; 49 (5): 2109–11.Bozdogan B, Appelbaum P.C., Kelly L.M. et al. Activity of telithromycin compared with seven other agents against 1039 Streptococcus pyogenes pediatric isolates from ten centers in central and Eastern Europe. Clin Microbiol Infect 2003; 9: 741–5.Alos J.I., Aracil B, Oteo J et al. High prevalence of erythromycin - resistant clindamycin/miocamycin - susceptible (M - phenotype) Streptococcus pyogenes: results of a Spanish multicentre study in 1998. J Antimicrob Chemother 2000; 45: 605–9.Grivea I.N., Al-Lahham A, Katopodis G.D. et al. Resistance to erythromycin and telithromycin in Streptococcus pyogenes isolates obtained between 1999 and 2002 from Greek children with tonsillopharyngitis: phenotypic and genotypic analysis. Antimicrob Agents Chemother 2006; 50 (1): 256–61.Szszypa K, Sadowy E, Izdebski R et al. A rapid increase in macrolide resistance in Streptococcus pyogenes isolates in Poland during 1996–2002. J Antimicrob Chemother 2004; 54: 828–31.Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность Streptococcus pyogenes в различных регионах России: результаты многоцентрового проспективного исследования ПеГАС-I. Клин. микробиол. антимикроб. химиотер. 2005; 7 (2): 154–66.Seppala H, Klaukka T, Vuopio-Varkila J et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med 1997; 337 (7): 441–6.Logan L.K., Mc Auley J.B., Shulman S.T. Macrolide treatment failure in streptococcal pharyngitis resulting in acute rheumatic fever. Pediatrics 2012; 129 (3): e798–802.Mc Carty J, Hedrick J.A., Gooch W.M. Clarithromycin suspension vs penicillin V suspension in children with streptococcal pharyngitis. Adv Ther 2000; 17: 14–26.Mehra S, van Moerkerke M, Welck J et al. Short course therapy with cefuroxime axetil for group A streptococcal tonsillopharyngitis in children. Pediatr Infect Dis J 1998; 17: 452–7.Adam D, Hostalek U, Troster K. 5-day therapy of bacterial pharyngitis and tonsillitis with cefixime: comparison with 10 - day treatment with penicillin. Klin Padiatr 1996; 208: 310–3.Tack K.J., Hedrick J.A., Rothstein E et al. A study of 5-day cefdinir treatment for streptococcal pharyngitis in children. Cefdinir Pediatric Pharyngitis Study Group. Arch Pediatr Adolesc Med 1997; 151 (1): 45–9.Pichichero M.E., Gooch W.M., Rodriguez W et al. Effective short - course treatment of acute group A beta - hemolytic streptococcal tonsillopharyngitis. Ten days of penicillin V vs 5 days or 10 days of cefpodoxime therapy in children. Arch Pediatr Adolesc Med 1994; 148 (10): 1053–60.Mc Neil S.A., Halperin S.A., Langley J.M. et al. Safety and immunogenicity of 26 - valent group A streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 2005; 41: 1114–22.Casey J.R., Pichichero M.E. Higher dosages of azithromycin are more effective in treatment of group A streptococcal tonsillopharyngitis. Clin Infect Dis 2005; 40 (12): 1748–55.Altamimi S, Khalil A, Khalaiwi K.A. et al. Short versus standard duration antibiotic therapy for acute streptococcal pharyngitis in children. Cochrane Database Syst Rev 2009; (1): CD004872.